We value our partnerships with the media and welcome any inquiries about the ACG Group. Please use the resources on this page, or if you have any specific queries please reach out to the media contact listed below.
ACG to boost Mexico presence with appointment of Jessica Alfaro
ACG Engineering, a division of ACG, the world's only integrated pharmaceutical solutions and manufacturing company, is delighted to announce the appointment of Jessica Alfaro as territory sales manager for the Mexico region, as the company seeks to vastly increase its presence in the territory. In her new role, Jessica Alfaro will be responsible for promoting ACG’s portfolio of process and packaging machinery in Mexico, establishing new bonds with customers through the commitment of providing integral solutions to improve their processes. With a passion for engineering, Jessica previously worked as a sales engineer for Nicolás, Sven, Pacheco Y Andresen, Design and Engineering. Her responsibilities included the monitoring of technical specifications and industry standards, as well as the continuous development of the overall product offering. She also led board sessions, assigning requirements to valid use cases that highlighted the capabilities of the product. In addition, she worked closely with customers and the engineering team to determine the needs of the process and the requirements of the system. Commenting on the appointment, John Carey, vice-president of Sales at ACG Engineering, said: “We’re delighted to welcome Jessica into this pivotal new role. ACG is currently placing real focus and investment in the Mexico region for our process and packing machinery supporting both pharmaceutical and nutraceutical manufacturers with state-of-the-art technologies. We believe her experience and dedication will play a key part in building strong customer relations in the area.”Jessica Alfaro added: “I am delighted to be joining ACG, and embracing the challenges associated with gaining a deep understanding of our clients and providing them with the best solutions to help drive their business success. “I am excited by the idea of applying my analytical skills to design efficient and sustainable processes. My chemical engineering background gives me the opportunity to merge my passions for problem solving and teamwork, allowing me to contribute to the development of technologies and solutions that have a positive impact on the world around us.”About ACGFor over sixty years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Vantage Nutrition to champion ‘better delivery’ at Vitafoods Europe 2024
At this year’s Vitafoods Europe, Vantage Nutrition (an ACG group company), will be showcasing and championing the term ‘better delivery’. With a real focus on innovation, the team will be debuting the outstanding beadlet technology, a complete product offering ultimate ingredient performance.Other ACG Capsules products on show will include ACGcaps™ H+, the world's first independently certified* ‘Clean Label' eco-friendly capsule, which is made using thermogelation technology (water and cellulose only). Alongside will be the ACGcaps™ TSafe opaque and TiO2-free clean capsules, with the enhanced version offering flexibility with pigmentation options.Aaron Quinn, head of business development at Vantage Nutrition – Europe, commented: “We know that the world’s healthiest products demand the world’s cleanest capsules performance through more advanced technologies. Through our innovations, we are committed to supporting nutraceutical brands when it comes to time consuming and costly R&D.“With the development of beadlet technology we are able to offer ultimate ingredient performance and enhanced delivery. Beadlets release ingredients over time, boost absorption and improve bioavailability. And by working with one supplier, manufacturers can ensure they have full control over all processes, with the 360 service – ensuring better results and enhanced uptake.”ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical solid dosage products and services. Along with the commitment to delivering integrated solutions and cutting-edge technology, Vantage Nutrition aims to provide the most comprehensive and advanced multiphase solutions to customers globally. The team’s focus in on turning product ideas into reality fast – helping companies enable, enhance, and differentiate nutra brands - from a full-service partnership to specific value additions.ACG will be exhibiting on stand H37, between 14-16 May in Geneva.* Certifications are applicable to certain colours and/or variants.About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Becomes the World’s First Capsule Manufacturing Factory to Join the Global Lighthouse Network Community 2023-24
ACG Capsules Pithampur, India is ACG’s 1st lighthouse to join the community Karan Singh, Managing Director and Balajikasiram Sundararajan, Chief Digital Officer attend the Global Light House Network ceremony in Davos to collect the award. ACG, the world's largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum at the 54th Annual Davos Summit. The World Economic Forum’s Global Lighthouse Network has acknowledged the exemplary integration of Fourth Industrial Revolution (4IR) technologies, including artificial intelligence and big data analytics, by select factories globally. These facilities have been distinguished for their commitment to enhancing efficiency, fostering sustainable development, and simultaneously advancing their workforce’s skills and safeguarding the environment.Upon receiving the award, Mr. Karan Singh, Managing Director, said: “I am delighted to receive this recognition on behalf of my team. For me the most unforgettable part of our journey wasn't any technology or efficiency milestone, but the incredible team that made it all possible. Just ordinary people, united towards one goal, bringing about innovative collaborations to push boundaries of what is possible.” He added: “One of the stand-out features of our application was the Gen-AI integration. Something that was done in the less than two weeks. In between all the debate on what Gen-AI can do to humans it is a beautiful reminder that ‘technology is brilliant, but humans drive the change’. Let's remember that!”ACG operates across 138 countries in six continents and has positioned itself as a leader in the pharmaceutical sector by focusing on high-quality capsule production, increasing responsiveness, improving production yields, and boosting workforce efficiency. The company produces billions of capsules annually and has implemented over 25 innovative applications of 4IR technologies, including the industrial internet of things (IIoT), machine learning (ML), deep learning (DL), digital twins, extended reality, and generative AI.Selwyn Noronha, CEO, ACG Capsules, added: “We are extremely proud of our first factory lighthouse. From its inception the facility has pioneered in its field, but this latest honour recognises the excellence in adopting AI at speed and scale.“Our continued future-focused approach sets new benchmarks in quality and innovation, with the aim of ensuring maximum benefit for customers, regulators and the entire pharmaceutical ecosystem.”About Global Lighthouse Network Global Lighthouse Network is a collaborative platform bringing together forward-thinking manufacturers leading the charge in adopting Fourth Industrial Revolution technologies. Leveraging innovations like artificial intelligence, 3D-printing, and big data analytics, Lighthouses drive efficiency, competitiveness, and transformative business models at scale, fostering economic growth while championing workforce augmentation, environmental protection and providing a collaborative learning journey for all-sized manufacturers globally. The Global Lighthouse Network is a World Economic Forum initiative co-founded with McKinsey & Company and counselled by an Advisory Board of industry leaders, including Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koç Holdings, Schneider Electric, and Siemens. Factories and value chains that join the network are designated by an independent panel of experts.About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards. Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACHEMA 2024: ACG Engineering on a mission to collectively ‘Make it Better’ World’s largest integrated supplier to the solid dosage manufacturing industry to display wide range of engineering and capsules products
At ACHEMA 2024 ACG Engineering, which provides end-to-end pharmaceutical engineering solutions,will be displaying its broadest range of products to date – underlining its commitment to ‘Making it Better’ for the industry and patients alike.The all-encompassing machines displayed will include the QUEST FB I, which is a highly versatile 'plug and play' fluid-bed unit for lab-scale feasibility studies. Also on show will be the ZRO 90T - a high-yield capsule filler. As will be the ACCURA 100FF - ACG's precision capsule checkweigher, suited for medium to large production batches with a capacity of 100,000 capsules per hour. Also on display will be the PROTAB 300 – a single rotary tablet press, which is suitable for R&D, small and medium-batch production, making scalability far easier, and the SECURECOAT TC III tablet coater, designed with operator safety and for use with highly potent active pharmaceutical ingredients (HPAPIs).Borja Guerra, vice president of international sales at ACG Engineering, said: “At ACG, we deliver efficient cutting-edge technology and a highly consistent ROI ratio for our global customer base, because we actively listen to them and their needs and take a collective approach towards ‘Making it Better’.“By aligning our shared strength and cross-divisional synergies with our Capsule and Films and Foils business units we are able to offer a whole world of different and highly targeted products and services – supporting large pharmaceutical companies and generic manufacturers with equal focus.”“We are really looking forward to ACHEMA 20024 and meeting with the industry to share knowledge and insights and to hopefully forge some new and exciting partnerships, continuing the expansion of ACG’s global footprint.”ACG will be exhibiting on stand A71 in Hall 3.1, between 10-14 June in Frankfurt.-Ends-About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year
ACG, the world’s largest integrated supplier and service provider to the pharmaceutical industry, is delighted to announce that for the fourth consecutive year, it has achieved the ‘Great Place To Work’ certification. This certification recognises employers who create an outstanding employee experience.Within ACG, five business units (Capsules, Corporate, Scitech – Research and Development Centre, Machinery, and Inspection), have been certified as a ‘Great Place to Work’. The comprehensive study, spanning five locations in India, encompassed approximately 3000 associates across management and plant categories. The process entailed a thorough survey based on key levers that define an organization's culture.Nikita Panchal, Group Head Talent, OD and DEI at ACG, said: “Winning this award for the fourth consecutive year fills me with pride and gratitude, recognizing the collective effort of our associates. It serves as a reminder of our commitment to excellence and the fact that institution-building is at the centre of all our actions as an organization.“ACG fosters collaboration by nurturing teamwork and effective communication. We care for our associates and the business community through support initiatives, and we remain progressive by supporting change and innovation. Our associates are encouraged to embrace our values, seize opportunities for growth and contribute their unique talents to shape a bright future together.”Sunil Jha, Group CHRO of ACG Group, added: “ACG thrives on collaboration through cross-functional teamwork, and – at all times – we prioritize the wellbeing of our associates.“Winning this award is incredibly gratifying and I am appreciative that all our associates have worked together to make this happen.”-Ends-About ACGFor over sixty years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Interphex 2024: ‘ACG focuses on lowering manufacturer’s TCO’
At this year’s Interphex, ACG Engineering, part of ACG - the world's only integrated pharmaceutical solutions and manufacturing company - will be focusing on its cost-effective approach to taking generics to market.ACG’s methodology is based on speed-to-market, production efficiency and reducing manufacturing costs.Borja Guerra, vice-president of international sales at ACG, said: “As a highly experienced global supplier of process and packaging machinery of all oral solid dosage requirements, we are attuned to local market requirements. We aim to provide a low TCO (total cost of ownership) for premium pharmaceutical equipment.“With over six decades of experience partnering in the oral solid dosage space, we have taken over 8000 generics to market, working with more than 1000 pharmaceutical manufacturers to achieve this.”ACG will be showcasing its ACCURA 100 FF. The capsule checkweigher is designed specifically for precise, automatic, and continuous weighing of each capsule – whether empty, filled or partially filled, with anything from powder to pellets, and which is format free.ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical solid dosage products and services. The company will be exhibiting on stand 3515 between 16-18 April in New York.About ACG For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Inspection launches new cloud-based offering to address upcoming VRS requirements under DSCSA regulations
In light of the impending Drug Supply Chain Security Act (DSCSA) regulations, ACG Inspection, a leading track and trace solutions provider for the pharmaceutical industry, has launched its new cloud-based Verification Router Service (VRS).The new system, which forms part of the ACG’s Inspections Life Sciences Cloud Service and Compliance Gateway, enables the automatic verification of saleable returns through product identifiers by routing requests and responses between stakeholders. Serialized products are assigned a unique identifier that can be used to track the product throughout its entire journey, enabling wholesalers to verify the authenticity of the products before they are resold.Shine Vijayan, CTO at ACG, commented: “The regulations, which have now been delayed by 12 months (coming into force in November 2024), will require all trading partners in the pharmaceutical supply chain to verify the identifier of any serialized drug product before redistributing it.“ACG’s existing VeriShield solutions tackles the implementation and interoperability challenges faced at Level 1, through to Level 3. With DSCSA’s regulation in place, ACG’s VRS covers level 4 - helping pharmaceutical manufacturers, distributors and retailers easily track and verify the saleable returns and secure their supply chain from counterfeit and substandard products.“ACG works closely with its customers, helping to address their pain points - one of which being concerns around data security. Our VRS employs robust security measures to safeguard serialized product information, guaranteeing the confidentiality and integrity of sensitive data throughout the verification process.”The system also guarantees real-time verification, to enhance operational efficiency and prevent supply chain delays. Additionally, it provides scalability assurance to accommodate an expanding volume of serialized data, to ensure continued robustness and reliability. And it incorporates exception handling, empowering stakeholders to address issues promptly to help maintain supply chain integrity.Shine Vijayan: “We are trusted experts and through our Life Sciences Cloud Service and Compliance Gateway, we can support counterfeit prevention, improving recall efficiency and data security. At all times, ensuring our clients are fully compliant with international standards and ready to meet the requirements as laid out in the impending DSCSA regulations.” -Ends- About ACGFor over sixty years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve. For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Engineering launches the Smart Coater X.ONE Series Company’s fastest tablet coater ensures optimised production processes
ACG Engineering, a division of ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is delighted to launch its new Smart Coater X.ONE series, the company’s fastest tablet coater to date.The Smart Coater X.ONE has been designed to make tablet coating extremely fast, with an extra emphasis on process speed, efficiency and operator ease. Its advanced baffle design ensures the quickest process times for batches from 10-100%.Features of the new coater include a unique airflow pattern for optimized drying, a fully-perforated coating drum, closed dust-free charging, integrated discharge baffles, temperature sensor, a high-performing spray-arm and a 2.0 spray nozzle which has been developed with an anti-bearding cap. It also incorporates ACG’s exclusive X•ONE command and control system, designed to facilitate compliance with cGMP standards. Richard Stedman, CEO at ACG Engineering, said: “Our Smart Coater machines are already renowned for their innovative features and operator friendly designs. Now, after a lengthy period of development, we are excited to announce the launch of the X.ONE series.“Our quality-commitment philosophy means that the new machine has been crafted to achieve maximimum efficiency and flexibility for superior tablet coating, across every process – from charging to coating, discharging to cleaning. Each and every cycle is now swifter, more streamlined and profitable.“The fast tablet coater to date is already garnering real interest, and we look forward to continuing to showcase it capabilities at the upcoming CPhI event in Barcelona at the end of the month.” (XXX – may want to adapt this sentence, to reflect true accuracy)-Ends-About ACGFor over 60 years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG acquires Technical Aluminium Foil Company
Further underpinning business growth across the Middle Eastern and African marketsACG announces full shareholding ownership of Technical Aluminium Foil Company (TAFC). This strategic move further solidifies ACG's growth trajectory across the Middle Eastern and African markets.As the world's only integrated pharma manufacturing solutions company, ACG offers a diverse range of products including capsules, films, foils, engineering equipment and inspection systems. The addition of TAFC, a prominent aluminium foil packaging company based in the UAE, strengthens ACG's position as a leading provider of comprehensive packaging solutions.TAFC boasts over a decade of experience serving the pharmaceutical and food industries with its extensive range of aluminium and specialty packaging foils renowned for their exceptional high barrier properties. The company's expertise in lacquering, lamination, printing and slitting further enhances ACG’s capabilities in meeting the diverse packaging needs of its clients.This acquisition represents ACG Group's inaugural venture in the Middle East, following recent successful acquisitions of ComboCap and AquaCap in the Americas. TAFC seamlessly aligns with ACG Films and Foils' existing business operations, enabling both entities to harness their collective strengths and expertise for accelerated growth.Shivshankar S.R., CEO at ACG Films & Foils, said: “We are excited to be making our first acquisition in the UAE. This strategic collaboration will further support our work in bringing innovative and high-quality packaging products to market, while reducing lead times and improving service levels.“By joining forces, the companies will be able to leverage their combined strengths and expertise to propel the business forward in the Middle Eastern and African markets.”-Ends-About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Vantage Nutrition LLC acquires ComboCap Inc
This acquisition positions Vantage Nutrition as the only company in the world supplying Sidebysideä health products to nutritional and pharmaceutical markets, for enhanced combinations.Vantage Nutrition, an ACG group company announces full shareholding ownership of ComboCap Inc (USA) and BioCap (South Africa).ComboCap is renowned for the invention and commercialization of its Sidebyside technology, the world’s first three-piece capsule health product that contains an internal divider, enabling wet and dry ingredients to be brought to market side by side, separated-but-together. Backed by 80 international patent awards ComboCap has been supplying nutritional brand customers with unique finished product solutions out of its cutting-edge cGMP plant in NJ, USA. This acquisition marks a significant milestone for Vantage Nutrition and ACG, as it further expands its technology and customer solutions footprint in North America and around the world.ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical solid dosage products and services. Vantage Nutrition, an ACG group company, already has an excellent reputation as an innovator of liquid filled capsule solutions. ComboCap marks Vantage Nutrition’s second US investment in less than a year, and first in S.A, after Philadelphia-based ‘AquaCap’ was acquired from Nestlé S.A. With this expansion of manufacturing capabilities and patented technology, along with the commitment to delivering integrated solutions and cutting-edge technology, Vantage Nutrition aims to provide the most comprehensive and advanced multiphase solutions to customers globally.Karan Singh, Managing Director at ACG, said, "As one of world’s largest producers of empty hard-shell capsules, at ACG we have often thought, what next? Strengthening our portfolio of most comprehensive vegetarian and gelatin capsules, in every imaginable size, I am thrilled to announce the acquisition of ComboCap Inc and BioCap. We now will hold the patented design and specialized equipment used inproducing the world’s first 2-in-1 capsule product with a movable membrane, becoming the sole proprietor of this technology globally.With our partners, we will usher a new era in new combinations of dietary supplements, and even non-prescription or over-the counter (OTC) remedies as well as prescription (Rx) medicines to be delivered in a single dose. This technological breakthrough is a solution to current formulation challenges with many combination therapies, including incompatible ingredients or molecules. Capsules are arguably the safest and most reliable way to deliver medicine and we at ACG strive to make it better.”Tobie Louw, a Founder and CEO of ComboCap Inc, said: “Vantage Nutrition is the perfect partner for our business, and we are very excited to be part of the ACG family. We share a passion for innovation and the commitment to bring nutraceutical and pharmaceutical customers the best possible solutions and services. By joining forces and leveraging our collective capabilities we’ll no doubt bring Sidebysideä to nutraceutical and pharmaceutical markets the world over.”-Ends-About Vantage NutritionVantage Nutrition, part of the ACG Group, is one of the world’s largest and most respected manufacturer of hard-shell liquid-fill capsule solutions. As a strategic consultancy and manufacturing partner in the nutraceutical space, Vantage Nutrition helps clients bring high-quality and innovative products to market, fast. About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Engineering – SECUREFILL 40T
Tablets & CapsulesCapsule Filling Equipment & Supplies (February 2023)ACG Engineering – SECUREFILL 40TThe Securefill series is ACG’s high-level containment capsule-filling machine range. Designed for filling capsules with highly potent and/or toxic drugs, the machines comply with occupational exposure band (OEB) up to level 4.Built with operator safety in mind, these machines are equipped for filling capsules with oncological, biopharmaceutical, antiviral formulations, and other such highly potent active pharmaceutical ingredients (HPAPIs).Features:• SS316L monoblock structure containing HEPA filters, a rapid transfer port (RTP), glove ports, and accurate dosing mechanisms maintained in a negative pressure environment.• Provision for contained charging and discharging.• Wet-in-place system to ensure wetting of all suspended particles in the pharma zone.• Can be integrated with check-weighers, metal detectors and de-dusters under containment conditions.Benefits:• Ensures complete containment, thereby avoiding operator contact within OEL range 1-10µg/m3.• Integrated containment philosophy for upstream and downstream processes.• Enables easy cleaning.• Supports the production of life-saving drugs that contain HPAPIs.Technical specifications: SECUREFILL 40T Capsule size 00 - 5 Maximum speed 40,000 capsules/hour OEL 1-10µg/m3About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
Vantage Nutrition LLC acquires Aquacaps from Nestlé Health Science
Vantage Nutrition’s innovative nutraceutical offering expands into North America.. Vantage Nutrition, an ACG Group company, announced on 1st December 2022 that it has acquired Philadelphia-based ‘Aquacaps’ – an asset of Nestlé Health Science. Aquacaps is a leading contract manufacturer of liquid-filled capsules within the nutritional supplement industry in the United States. Its novel liquid delivery technology allows for the liquid filling of hard gelatin and vegetarian capsules. ACG is the world’s largest integrated supplier of pharmaceutical and nutraceutical products and services. Vantage Nutrition, an ACG group company, already has an excellent reputation as an innovator of two-piece liquid fill capsule solutions. The company’s mission is to be the most efficient partner in delivering innovative and high-quality nutraceutical products to customers globally. Karan Singh, Managing Director of ACG, said: “Although ACG has been established in North America for the last 20 years, this marks our first acquisition in the territory and is a key next step in our global expansion strategy. With this increase in our footprint and manufacturing capabilities, coupled with Vantage’s innovative technologies and 360-degree service offering, we aim to provide the most advanced combination liquid-fill solutions for customers across the region.” About VantageVantage Nutrition, part of the ACG Group, is one of the world’s largest and most respected manufacturer of hard-shell liquid-fill capsule solutions. As a strategic consultancy and manufacturing partner in the nutraceutical space, Vantage helps clients bring high-quality and innovative products to market, fast. About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG appoints Shankar Gupta as Chief Sales Officer Industry authority to re-join business in a newly created role
ACG, the world’s largest integrated pharmaceutical and nutraceutical manufacturing solutions provider, is delighted to announce that Shankar Gupta will be re-joining the business in the newly created role of Chief Sales Officer.In his new role, Shankar will be responsible for driving sales across all four ACG divisions (Films and Foils, Capsules, Inspection and Engineering) in order to continue building the company’s ‘One ACG’ agenda. Essentially, this will involve bringing further uniformity to ACG's customer outreach processes, creating more integrated solutions, and ultimately providing a consistent brand experience to ACG’s global customers, regardless of business division or location. He will also focus on scaling new initiatives.Shankar will report directly into the managing director, Karan Singh, who comments:"I am so pleased that Shankar Gupta has decided to rejoin the business during this exciting time. His understanding of ACG and its deliverables, and deep insight into our customers’ businesses will help us to align ourselves better to their changing needs. More importantly, he will champion and support better collaboration and partnership with customers.“Shankar will be pivotal in calibrating and aligning our business units to our goal of ‘Making it Better’, and our belief that everyone deserves access to good medicine."Shankar Gupta adds: “I am excited to use my experience in the pharmaceutical industry to augment ACG's growth by aligning the organisation to the changing dynamics of the global healthcare Industry.“It will certainly call for a huge collaboration of efforts both internally and with our customers, but will ultimately lead to a richer, deeper and more numerous partnerships.”-Ends-About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos. ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG to Launch German Process Laboratory in 2023
Following the success of its first-to-market laboratory for process development in India, ACG (the world’s biggest integrated pharmaceutical and nutraceutical manufacturing solutions provider) is now also committed to launching a sister process lab in Germany in 2023.This new process development laboratory will be located at ACG’s XERTECS GmbH site in Mulheim in the South West of Germany, with the first phase occupying approximately 250 square metres. ACG’s staffing recruitment plan for the lab will be to attract top academic talent from local universities, as well as trained and experienced process engineers, pharmacists and lab technicians.The aim of ACG’s new laboratory will remain consistent with the first – to provide customers and partners access to the latest knowledge, skills and equipment to collaboratively keep pushing the boundaries of all aspects of process development. So customers can test solid dosage optimisation limits, for example, and co-create alongside ACG’s team of experts to develop new process solutions.The extensive range of available equipment covers areas including feasibility studies, research and development work, pilot-scaling, and tailored in-house technical training courses. Customers also get to experience and test products from ACG’s portfolio and gain operational and maintenance training on premise.Dr Marcus Michel, CEO of ACG Engineering, explains: “ACG’s process labs reinforce our commitment to ‘making it better’. Requested by the Indian market, our first lab has enabled customers to build their competencies and capabilities, as well as to scale up – with many of these customers now operating at high capacity and efficiency. Our plan is simply to replicate this model in the European market, and we are working at full speed to ensure the launch of our new facility in 2023.“The lab in India is home to some of the smartest and finest technologies in powder processing, and is fully equipped for all aspects of granulation, drying, tablet compression and coating. Many of our machines are unique because they have been built or modified in direct response to our customers’ needs – helping them on their manufacturing journey.”About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for over sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos, and ACG is the world’s only fully integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG appoints Udit K Singh as CEO of ACG Inspection
ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industry, is pleased to announce the appointment of Mr. Udit K Singh as the new chief executive officer (CEO) of its Inspection Division.Mr. Singh will be supporting the company as it continues its growth and global expansion. He will be responsible for ensuring that every dose of medication that ACG Inspection’s pharmaceutical and nutraceutical partners provide is manufactured and delivered exactly as intended. That is down to the fact that ACG’s visual inspection systems track and monitor the manufacturing lines to guarantee flawless, safe products.Karan Singh, managing director, ACG said: “ACG is focused on building a diverse, world-class team by hiring top international talent. We are delighted to welcome Udit Singh to ACG Inspections. He has had an illustrious career and brings diverse and unique capabilities, including a robust understanding of the pharmaceutical sector.“The team looks forward to tapping into his deep experience to enrich our global work towards making the world safer and healthier. With his knowledge and expertise in this field, Udit Singh is sure to take ACG Inspection to newer heights.”Mr. Singh added, “I am pleased to join ACG and will work to ensure that our advanced serialisation, aggregation and anti-counterfeiting solutions track and protect medicines all the way through the supply chain, and into the hands of those who need them.“We are investing substantially to ensure our track and trace platform performs seamlessly and complies with regulatory requirements all over the world. I look forward to playing an integral role, and contributing towards the continued development, working with a world-class team.”About ACGIn accordance with its commitment to making the world healthier, ACG has been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for almost sixty years, across six continents and in a hundred countries.Collaboration is at the core of ACG’s ethos, and ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment and inspection systems – all that meet international regulatory requirements. For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
ACG Capsules launches campaign to promote problem-free pharmaceutical production
-One of the world’s largest producers of empty hard-shell capsules is on a mission to‘Love NOTHING’ when it comes to zero-problem productionACG, one of the world’s largest producers of empty hard-shell capsules, has launched its global pharmaceutical campaign: ‘ACG loves NOTHING’. The campaign is aimed at significantly improving pharmaceutical production through collaboration and industry-leading innovation. With a host of value-added services on offer, ACG has taken a pledge to strive for zero-problem pharmaceutical and nutraceutical manufacturing.Alex Robertson, CMO at ACG, said: “The messaging at the centre of this campaign is: ‘ACG loves NOTHING’ – we are putting every effort towards zero-problem production. That’s because when ‘nothing’ happens during pharmaceutical and nutraceutical production, everything runs reliably, and our customers can get the products they make to the people who need them. We will achieve this by providing the highest quality empty capsules and all the holistic advice and expertise required for seamless operations.”Founded 60 years ago, ACG was created on the simple principle of ‘Make it Better’. As the world’s largest integrated supplier of solid dosage pharmaceutical and nutraceutical products, and with the most comprehensive ranges of vegetarian and gelatin capsules globally, ACG has the scale and range to have a far-reaching impact on pharmaceutical production and human health.Selwyn Noronha, CEO ACG Capsules, added: “The pharmaceutical sector is regulated and highly competitive. Companies operating within it need a diverse range of quality capsules that help them stand out from the crowd, while also meeting demands for clean and natural products.“Beyond exceptional products, these companies need expertise and a lifetime of targeted support to ensure efficient manufacturing and guarantee regulatory compliance. With proficiency in all aspects of manufacturing from capsules to machines and protective barriers, for the last 60 years ACG has been the only company to offer this level of support, and it continues with this focus at the heart of operations.”So, at ACG, there really is something about NOTHING. The company is on a mission to drive towards problem free production and collaborating with its customers to collectively deliver on its mission of creating a healthier world.About ACGIn accordance with its commitment to making the world healthier, ACG has now been delivering exceptional solutions to the global pharmaceutical and nutraceutical industry for 60 years, across six continents and in 138 countries.‘Collaboration’ is at the core of ACG’s ethos, and ACG is the world’s only integrated pharma manufacturing solutions company, with products ranging from capsules to films & foils, to engineering equipment, and inspection systems – all that meet international regulatory requirements.For ACG, it’s always about finding innovative solutions to the world’s greatest health challenges, together.For more information, please contact the ACG media relations team:madhurima.chakraborty@acg-world.com
Read more
MD Karan Singh explains the journey in achieving the “Oscars of manufacturing”
ACG’s Moonshot Moment : becoming part of WEF’s GLN community
Last month, India’s largest capsules maker and the world’s second-largest – ACG – was feted in Davos, on joining the World Economic Forum’s Global Lighthouse network.“Lighthouses” are a beacon of sorts, when it comes to adopting advanced technologies to transform manufacturing, and globally there are 153 certified Lighthouses, across industries.ACG Managing Director Karan Singh explains their journey in achieving the “Oscars of manufacturing”. As a supplier to every other pharma company in India and major global companies – the milestone puts it in a small and elite group that is implementing advanced manufacturing technologies and boosting productivity, sustainability and supply chain resiliency - a beacon for others in the industry.Listen to the podcast at - Spotify, Apple Podcasts and Official Website.( Host: PT Jyoti Datta, Producers: Nabodita Ganguly & Siddharth Mathew Cherian)-----About the State of the Economy podcastIndia’s economy has been hailed as a bright spot amid the general gloom that seems to have enveloped the rest of the world. But several sectors continue to stutter even as others seem set to fire on all cylinders. To help you make sense of the bundle of contradictions that the country is, businessline brings you podcasts with experts ranging from finance and marketing to technology and start-ups
Read more
Multi-particulate Formulations
Multi-particulate Formulations - Tablets or Capsules?
After assessing the various routes of drug administration, oral delivery stands out as the safest and, as a result, the most universally accepted among patients. In this context, single-unit dosage forms, including tablets followed by capsules, have been identified as the preferred designs for immediate or modified release formulations. In addition, multiple-unit dosage forms, comprising of discrete particles like pellets or minitablets combined in a single dosage unit, have also gained significant popularity due to their benefits.Multi-particulate Formulations: The Power of ManyTraditionally, these multi- particulates are filled into empty hard capsules using automated capsule filling machines. However, more recent technologies have enabled the pellets to be compressed into multiple-unit pellet system (MUPS) tablets or pellet-containing tablets. Once these special tablets are exposed to the aqueous environment of the stomach, they disintegrate rapidly into individual pellets, releasing the drug like uncompressed pellets filled in capsules. MUPS technology has gained considerable acceptance, particularly in the European market, with a number of products coming to the fore, including: Beloc® ZOK (Metoprolol Succinate SR plus Hydrochlorothiazide), Antra® MUPS (Omeprazole) and Prevacid® SoluTabTM (Lansoprazole), Nexium (Esomeprazole), Galanil PR (Galantamine HBr), Lipidown (Orilistat), Esomezol (Esomperazole SR), TOP ROL XR (Metoprolol Succinate) and Cartia (Diltiazam).Since the total drug is divided equally into many units in a multiple-unit system, it demonstrates several advantages over single-unit systems. When administered orally, these particles (less than two mm in size) distribute evenly across the extensive surface area of the stomach. They behave like fluids and have a shorter retention time. Their small size also facilitates uniform gastric distribution, potentially reducing food induced variations in inter-and intra-individual bioavailability, minimizing chances of side-effects and local toxicity. MUPS tablets can also greatly reduce the risk of premature dose dumping leading to drug degradation or gastric irritation due to any failure in functional coating. This is because a failure of a few units may not be as detrimental as the failure of a single-unit system. Moreover, MUPS tablets also offer the possibility of adjusting dosage strengths, administering incompatible drugs together and combining multi-particulates with different drug-release rates to customize the release profiles.However, despite the various advantages that this unique dosage form provides, the appropriate presentation of these multiple units in the final formulation must be carefully considered. Should these pellets be filled in capsules or compressed into tablets? The best way to determine this depends on a comprehensive understanding of the overall formulation and manufacturing process of the MUPS technology.Key Variables in MUPS Tablet DevelopmentUnlike capsules, MUPS technology requires special excipients and critical process parameters to enable safe and easy compression. This ensures the pellets retain their properties, and that their drug release profile is unaffected. Some of the essential variables determining the success of MUPS tablets include:• particle size of coated pellets,• flexibility and thickness of functional coating,• type and quantity of cushioning agent, • and tablet compression forceIn capsule filling, there are no size limitations for pellets. Usually, larger pellets are preferred as they are easy to manufacture and handle. However, for MUPS, a smaller particle size of pellets is preferred as they are easy to compress and present minimal risk of pellet damage. Special excipients, also referred to as cushioning agents, are used as extra granular material for compression. Since these excipients are available in the powder state, they are often granulated to improve the particle size and density that help to ensure a homogenous distribution of the pellets in the excipient blend. It also minimises the possibility of size separation on the turret during tablet compression, thus maintaining content uniformity in the tablets.It is also important to realize that, by virtue of using smaller-dimension pellets, the resultant surface area increases exponentially as the particle size decreases. This demands higher polymer coating build up, which adds to the processing time and raw material cost. Moreover, the functional polymer coating must be flexible enough for the pellets to deform but not rupture under high compression force. This is typically addressed by using polymers that are inherently flexible or by adding the optimum amounts of plasticizers. Usually, a higher coating build up is preferred in these formulations to compensate for any slight damage without compromising the release profile. Finally, from a process perspective, the compression pressure is the most critical parameter. The mechanical properties of MUPS vary significantly from conventional tablets. Therefore, the compaction force required for pellets and powdered excipients are also very different. And the process becomes more critical if the pellets are functionally coated to modify the drug release. This requires an extremely tightly controlled manufacturing processes. For example, the range of compression force is kept narrow to ensure optimum pressure. Higher compression forces can damage the pellets, while low and inadequate compaction can result in friable tablets. The development of dedicated tablet compression machines with special turret designs and reduced vibration in recent years has helped to prevent blend segregation during operations.Despite all precautions, there remains the potential for pellet damage and the drugs being exposed to the external environment. This can sometimes manifest as minute spots on the surface, which are especially noticeable in sensitive Active Pharmaceutical Ingredients (APIs). However, in most cases, the therapeutic potency may not be significantly compromised. But, since such colour changes interfere with the aesthetics of the final formulation, an additional film coating becomes necessary to mask any possibilities of market rejections.A Prescription for the Drug Delivery DilemmaThe entire MUPS development process is a complex one. The combined impact of the raw materials along with critical process variables makes it extremely labour-intensive, time consuming and expensive. In the case of capsules, however, the absence of additional excipients, ready-made shells to fill, and a simple capsule filling process ensure far less complexity. Moreover, for scaling up or down pellet production for different strengths, capsules are much easier to handle. The absence of any extra granular powder excipients eliminates the possibility of dust generation, thus ensuring a safer and clean working environment. From a patient perspective, capsules also cater to pediatric and geriatric patients with swallowing difficulties by allowing the dispersion of multi-particulates directly into liquid or soft food, usually referred to as the “sprinkle” application. Moreover, encapsulating pellets doesn’t require any additional or specialized infrastructure, expertise, or technology since it employs a standard capsule filling process.Tablets are often favoured over capsules due to the lower production costs, but it is important to look at the bigger picture here. The total cost of ownership (TCO) for developing MUPS tablets extends beyond initial expense, requiring a high degree of precision that is achieved using not only specialised excipients and machinery but also expertise. These often-overlooked factors and hidden costs necessitate the importance of a comprehensive TCO analysis in making informed decisions about choosing the right drug delivery system.The questions we need to anwer include: is it worth developing a product loaded with so many risk factors? Why do ailing patients need to be exposed to unnecessary excipients with added costs? Why are simple available options no longer considered simple? Why are aesthetics more important than patients’ health? It is high time that we, the custodians of health, take cognizance and act accordingly for a better, healthier future.- Dr. Subhashis Chakraborty, Head, Global Product Management, ACG Capsules- Ananya Sen, Corporate Marketing, ACG GroupSource: https://www.pharmaindustrial-india.com/
Read more
ACG Joins List of WEF’s Global Lighthouse Network
ACG Joins List of WEF’s Global Lighthouse Network
ACG recently announced the inclusion of its capsule manufacturing facility in Pithampur, India, into the Global Lighthouse Network (GLN) by the World Economic Forum (WEF). WEF’s Global Lighthouse Network is a community of manufacturers which shows leadership in using Fourth Industrial Revolution technologies to transform factories, value chains and business models, for compelling financial and operational returns. The GLN has experienced exponential growth since its inception, expanding from 16 to 153 lighthouses. This initiative is a collaboration between WEF and Mckinsey & Company with independent panel of experts designating factories and value chains that join the GLN.The certification comes after audits of 25-plus use cases for the facility that have not only led to manufacturing of superior quality products but also, transformed operations creating new benchmarks for timely production, according to the company. ACG added that the company’s Pithampur factory exemplifies accelerated deployment of GenAI, addressing the evolving skill sets of employees in manufacturing through a Standard Operating Procedure (SOP) and policy interfacing with GenAI.“When ACG embarked on its journey to digital transformation, I recall how Industry 4.0, AI and ML were emerging concepts,” said Karan Singh, managing director of ACG Group. “The focus was directed toward deploying these technologies to enhance productivity and transform the way we operate; aiming to ultimately enhance accessibility to affordable medicines. With an ambitious and dedicated team, we forged a collective commitment to raise the bar of excellence in delivering high-quality capsules worldwide.”For more information, visit www.acg-world.com. Source: ACG Joins List of WEF’s Global Lighthouse Network
Read more
ACG joins coveted list of WEF's Global Lighthouse Network
ACG joins coveted list of WEF's Global Lighthouse Network
ACG, the world's largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum. WEF's Global Lighthouse Network is a community of manufacturers which shows leadership in using Fourth Industrial Revolution technologies to transform factories, value chains and business models, for compelling financial and operational returns. Remarkably, the GLN has experienced exponential growth since its inception, expanding from 16 to 153 lighthouses. This initiative is a collaboration between WEF and Mckinsey & Company with independent panel of experts designating factories and value chains that join the GLN. The certification comes after robust audit of 25+ use cases for the facility, that have not only led to manufacturing of superior quality products but also, transformed operations creating new benchmarks for timely production. ACG's Pithampur factory exemplifies accelerated deployment of GenAI, addressing the evolving skill sets of employees in manufacturing through a remarkable Standard Operating Procedure (SOP) and policy interfacing with Gen AI. Commenting on the recognition, Karan Singh, Managing Director of ACG Group said, "When ACG embarked on its journey to digital transformation, I recall how Industry 4.0, AI and ML were emerging concepts. The focus was directed toward deploying these technologies to enhance productivity and transform the way we operate; aiming to ultimately enhance accessibility to affordable medicines. With an ambitious and dedicated team, we forged a collective commitment to raise the bar of excellence in delivering high quality capsules worldwide." He further added, "6 years into the journey, I am filled with pride as my team paves a path for leading advance manufacturing and securing a position in the World Economic Forum's prestigious community of Global Lighthouses. This certification is a testament to our commitment to excellence and creating new benchmarks of facilities that are operating on the leading edge of technological innovation. In time to come, we envision taking the learnings and success from this facility to scaling global operations collectively to make it better for our partners, customers, regulators and eventually the pharmaceutical ecosystem." Known for its many accolades, ACG's Pithampur factory had incorporated green features right during the design and layout stages marking a pioneer achievement as they were certified gold by LEED in 2014. Sharing valuable insights and expertise on the state-of-the-art technological advancements, Balajikasiram Sundararajan, Chief Digital Officer, ACG group added "Build the Future, ACG's enterprise-wide digital transformation program is based on four strategic pillars - transforming operations, building smart connected products, enhancing customer experience, and developing digital led business models. Under the ambit of build the future, ACG has been actively developing and implementing state-of-the-art solutions, powered by digital technologies ranging from Industrial IoT, machine learning, deep learning, generative AI, cloud computing, to digital twins, industrial robotics, and extended reality. He further added, "These solutions have helped us to better serve our global customer base by solving critical customer-centric business problems. This prestigious Global Lighthouse recognition from the World Economic Forum further inspires us to continually explore innovative ways of leveraging digital technologies to re-imagine our entire value chain starting from our suppliers to our customers" Kiva Allgood, Head, Centre for Advanced Manufacturing and Supply Chains, World Economic Forum, said, "The Global Lighthouse Network exemplifies the power of digital transformation. Lighthouses are pioneering a path to unprecedented global impact, strategically weaving innovation throughout their expansive network - sculpting both a sustainable future and an era of transformative and lasting change."Press release from the World Economic Forum can be accessed here https://www.weforum.org/press/2023/12/factories-of-the-future-show-how-to-apply-ai-to-benefit-people-planet-and-performance/ About the Global Lighthouse NetworkThe Global Lighthouse Network is a collaborative platform bringing together forward-thinking manufacturers leading the charge in adopting Fourth Industrial Revolution technologies. Leveraging innovations like artificial intelligence, 3D-printing, and big data analytics, Lighthouses drive efficiency, competitiveness, and transformative business models at scale, fostering economic growth while championing workforce augmentation, environmental protection and providing a collaborative learning journey for all-sized manufacturers globally. The Global Lighthouse Network is a World Economic Forum initiative co-founded with McKinsey & Company and counselled by an Advisory Board of industry leaders, including Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koc Holdings, Schneider Electric, and Siemens. Factories and value chains that join the network are designated by an independent panel of experts. About ACGFor over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies. As the world's most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards. Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world's greatest health challenges and make it better for everybody we serve.For more information, please contact the ACG media relations team: madhurima.chakraborty@acg-world.com (ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same) Source: https://www.business-standard.com/content/press-releases-ani/acg-joins-coveted-list-of-wef-s-global-lighthouse-network-123121800955_1.html
Read more
ACG se junta à lista da Global Lighthouse Network do WEF
ACG se junta à lista da Global Lighthouse Network do WEF
A ACG, a maior fornecedora e prestadora de serviços para a indústria farmacêutica do mundo, comemora a inclusão de sua unidade de fabricação de cápsulas em Pithampur, na Índia, na reconhecida Global Lighthouse Network (GLN) pelo Fórum Econômico Mundial. A Global Lighthouse Network do WEF é uma comunidade de fabricantes que demonstra liderança na utilização de tecnologias da Quarta Revolução Industrial para transformar fábricas, cadeias de valor e modelos de negócios, obtendo grandes retornos financeiros e operacionais.A certificação surge após uma auditoria robusta de mais de 25 casos de uso para a instalação, que não só levaram à fabricação de produtos de qualidade superior, mas também transformaram as operações, criando novos padrões de referência para a produção. A fábrica da ACG em Pithampur exemplifica a implantação acelerada da GenAI, abordando os conjuntos de habilidades em evolução na fabricação por meio de um notável Procedimento Operacional Padrão (SOP) e interface de política com a Gen AI.Comentando sobre o reconhecimento, Karan Singh, Diretor Geral do Grupo ACG, disse: “Quando a ACG embarcou em sua jornada para a transformação digital, lembro-me de como a Indústria 4.0, IA e ML eram conceitos emergentes. O foco foi direcionado para a implantação dessas tecnologias para aumentar a produtividade e transformar a forma como operamos; com o objetivo de melhorar a acessibilidade a medicamentos. Com uma equipe ambiciosa e dedicada, estabelecemos um compromisso coletivo para elevar o padrão de excelência no fornecimento de cápsulas de alta qualidade em todo o mundo.”Ele ainda acrescentou: “6 anos de jornada, estou muito orgulhoso de ver a minha equipe abrindo caminho para liderar a fabricação avançada e garantir uma posição na prestigiada comunidade GLN do Fórum Econômico Mundial. Esta certificação é uma prova do nosso compromisso com a excelência e com a criação de novos padrões de referência em instalações que operam na vanguarda da inovação tecnológica. No futuro, pretendemos levar os aprendizados e o sucesso desta instalação para escalar as operações globais coletivamente e torná-la melhor para nossos parceiros, clientes, reguladores e também para o ecossistema farmacêutico.”A fábrica da ACG em Pithampur incorporou características ecológicas logo durante as fases de design e layout, marcando uma conquista pioneira, pois foi certificada ouro pelo LEED em 2014.Compartilhando informações valiosas e conhecimentos sobre os avanços tecnológicos de última geração, Balajikasiram Sundararajan, diretor digital do grupo ACG, acrescentou: “Construa o Futuro, o programa de transformação digital de toda a empresa da ACG é baseado em quatro pilares estratégicos - transformando operações, construindo produtos inteligentes conectados, melhorando a experiência do cliente e desenvolvendo modelos de negócios digitais. Pensando em construir o futuro, a ACG tem desenvolvido e implementado ativamente soluções de última geração, alimentadas por tecnologias digitais que vão desde IoT Industrial, aprendizagem automática, aprendizagem profunda, IA generativa, computação em nuvem, até gémeos digitais, indústria robótica e realidade estendida.O diretor reforça: “Essas soluções nos ajudaram a atender melhor nossa base global de clientes, resolvendo problemas críticos de negócios centrados no cliente. Este prestigiado reconhecimento Global Lighthouse do Fórum Económico Mundial inspira-nos ainda mais a explorar continuamente formas inovadoras de aproveitar as tecnologias digitais para estruturar toda a nossa cadeia de valor, desde os nossos fornecedores até aos nossos clientes”.Kiva Allgood, chefe do Centro de Fabricação Avançada e Cadeias de Fornecimento do Fórum Econômico Mundial disse: "A Global Lighthouse Network exemplifica o poder da transformação digital. Os faróis são pioneiros em um caminho para um impacto global sem precedentes, tecendo estrategicamente a inovação em toda a sua rede expansiva - esculpindo um futuro sustentável e uma era de mudanças transformadoras e duradouras.”O comunicado na íntegra do Fórum Econômico Mundial está diponivel no link: https://www.weforum.org/press/2023/12/factories-of-the-future-show-how-to-apply-ai-to-benefit-people%20-planeta-e-desempenho/Sobre a Global Lighthouse NewtworkA Global Lighthouse Network é uma plataforma colaborativa que reúne fabricantes com visão de futuro que lideram a adoção de tecnologias da Quarta Revolução Industrial. Aproveitando inovações como inteligência artificial, impressão 3D, os Lighthouses impulsionam a eficiência, a competitividade e modelos de negócios transformadores em escala, promovendo o crescimento econômico e ao mesmo tempo defendendo o aumento da força de trabalho, a proteção ambiental e proporcionando uma jornada de aprendizagem colaborativa para fabricantes de todos os tamanhos em todo o mundo.A Global Lighthouse Network é uma iniciativa do Fórum Econômico Mundial co-fundada com a McKinsey & Company e aconselhada por um Conselho Consultivo de líderes da indústria, incluindo Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koç Holdings, Schneider Electric e Siemens. As fábricas e cadeias de valor que integram a rede são designadas por um painel independente de especialistas. Sobre o Grupo ACGFundado em 1964 e operando no Brasil há 20 anos, o Grupo ACG é o único fornecedor mundial de soluções de fabricação integradas para a indústria farmacêutica. A empresa recebeu este ano o segundo lugar no Prêmio Sindusfarma de Qualidade, na categoria Fabricantes nacionais de matérias-primas. Conta com uma unidade fabril em Cotia (SP), a ACG Films & Foils, que oferece soluções em embalagens para as indústrias farmacêutica, alimentícia & FMCG (Fast-Moving Consumer Goods), e outra em Pouso Alegre (MG) focada na fabricação de cápsulas para as áreas farmacêutica e nutracêutica. Possui importantes certificações, como GMP, Halal e Kosher, se tornando um importante fabricante e distribuidor para todo o mercado doméstico, Latino-Americano, Norte-Americano e, recentemente, para a África. A ACG tem o compromisso com uma única meta: oferecer um portfólio completo de tecnologias e soluções integradas para a fabricação eficiente de sólidos orais. A multinacional está presente em mais de 100 países e tem mais de 4.500 funcionários em todo o mundo. https://www.acg-world.com/pt/EsclarecimentoA área Empresas em Foco publica notícias elaboradas e enviadas pelas empresas associadas ao Sindusfarma; seu conteúdo é de exclusiva responsabilidade das empresas e não reflete anuência nem posições ou opiniões da entidade.Source: ACG se junta à lista da Global Lighthouse Network do WEF
Read more
Richard Stedman appointed to CEO of ACG’s Engineering Division
ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceuticalindustries, has announced that Richard Stedman will rejoin the company as group chief executive officer of the Engineering Division. Throughout his career, Stedman has gained over 35 years of experience in the packaging, engineering and pharmaceutical manufacturing spheres, having led and transformed various businesses in multiple countries, including South Africa, Singapore, India, Australia and India.Stedman previously held the role of CEO of the Engineering Division at ACG from 2017 to 2021, and brings his wealth of engineering experience back to the role. Previously in this role, Stedman oversaw significant growth and achievement, including the successful completion of several high-profile projects. He was also a key player in expanding ACG’s presence in key global markets.Karan Singh, managing director at ACG, commented: “We are thrilled to have Richard back with us. Richard has a proven track record of success, and his leadership will be invaluable as we continue to grow and expand our operations.”Commenting on his reappointment, Stedman said: “I am excited to be returning to ACG Engineering as CEO. I have always had a deep respect for the company’s culture, values and commitment to excellence, and I look forward to working with the team to build on the success we have achieved in the past.”Commenting on his reappointment, Stedman said: “I am excited to be returning to ACG Engineering as CEO. I have always had a deep respect for the company’s culture, values and commitment to excellence, and I look forward to working with the team to build on the success we have achieved in the past.”Source: https://www.pharmafocus.com/
Read more
NBJ Nutrition Business Journal
NBJ Global Markets Overview - Q&A with Rafael Costa
Leading sales across North and South America for the mammoth contract manufacturer ACG, Rafael Costa keeps his feet on the ground in two hemispheres and a wide range of markets faced with a wide range of economic conditions and regulatory systems. We asked him for his quick thoughts on what he sees going on for supplements, looking south from the U.S.NBJ: Which of the South and Latin American markets are looking strongest right now? Costa: Brazil and Mexico are the two largest markets. Together, they represent 75% of vitamins and supplements sales in Latin America.NBJ: What are some of the categories driving growth in those markets? Costa: Vitamins, minerals and supplements, in general, are the predominant categories. In vitamins, historically the region has a predominance of vitamin C and calcium, the source being changed to calcium citrate malate. Most recently vitamin D, vitamin K2, zinc and magnesium have increased sales substantially. Within supplements, gastrointestinal (probiotics, fiber and enzymes), joint health (undenatured type II collagen, MSM and curcumin), sarcopenia (creatine), along with weight loss and multivitamins, drive most of the growth.NBJ: Which markets do you see as promising in the near-term future? Which channels are rising or fading? Costa: Brazil and Mexico are expected to keep growing. Also, Colombia and Chile are promising areas. In regard to sales channels, traditional retail is by far the largest sales channel and still growing, while online, MLM and direct selling are rising substantially. Compounding pharmacies also represent a big portion of the Brazilian market.NBJ: Where are the economic conditions impacting supplement sales? Costa: Political instability and economic conditions always have big impact on supplement sales across the Latin American market. Recent presidential elections have created an unsecure environment, which inhibits expenditure from population and investment from brands.NBJ: Do you see any changes in the MLM channel in the South American markets? Costa: For economic and regulatory reasons, in general, the MLM channel should continue to grow across Latin America, as it represents a unique opportunity to educate and better position supplements to most consumers versus other market channels.NBJ: What should U.S. companies understand about South America and what the future holds? Costa: In general, U.S. products and brands are well accepted across Latin America. A U.S. company interested in doing business in Latin America should understand the regulatory environment and legal requirements for that specific country. Each country has its own rules and what is feasible in Brazil could not be feasible in Mexico, for example. Finding a local partner, from a distribution to regulatory/ legal standpoint is key, to ensuring a successful product launch, and so you stay compliant with the local laws. Also, it is important to understand that most Latin American sales within the VMS segment come from pharmaceutical brands, as physician indication is still highly important for consumers’ decision making.
Read more
Virtual Inspections: Embracing the Digital Change
Virtual inspections must become a part of companies’ repertoires if they aim to maintain quality standards in their organisations.Digital tools and technologies are advancing rapidly – but how can pharma make the best use of them? One area of manufacturing that is ripe for enhancement via digital tools is product inspections.Udit K Singh, Chief Executive Officer at ACG Inspections explains.What historical challenges affect inspections today?Manual inspection methods increase the chance of rejecting an entire batch because of an anomaly in a single tablet or capsule from that batch. Whereas digital tools can identify defects at the individual product level – rejecting the defective products only. These tools also verify that the inspection has been carried out to the required parameters and that data, associated with the inspection, is stored.When inspecting products manually there is also the potential for defects to be missed. If these products reach the market, they can cause reputational damage to a brand, potentially resulting in lawsuits and revenue losses.Another historical challenge is that there hasn’t been any real-time qualification and analytics of manufacturing output. In my view, being able to provide assurance that each capsule or tablet has been qualified against the quality standards and a benchmark has been set by aggregators in this space is of crucial importance.What are the key benefits of digital inspections?The benefits of digital inspections are immense. Better throughput, improved quality outcomes and higher visibility are all possible to achieve when businesses choose to integrate digital inspections into their operations.Camera sensors use images captured to determine the chemistry, orientation, hardness and other product characteristics such as moisture. They work at high speed and on fast-moving production lines. Because they remove faulty products before they reach packaging the production performance is optimised. The operators just need to be trained to ensure the standard operating procedures (SOPs) are followed.Manual inspection is subjective. Humans require training and education and have limitations. For example, manual inspection makes it difficult to distinguish a “look-alike” product, minute variances in colour and other characteristics. Manual inspection is repetitive work, in often brightly lit conditions which means human performance will be varied and subject to fatigue – therefore the quality assurance cannot be validated.In the past, inspections at single points in a manufacturing plant, such as in-line and end-of-line product sampling were acceptable. Clearly, this type of check wouldn’t provide companies with a full picture. Digital inspections offer manufacturers the opportunity to create better data to support business decisions and the means to view the strengths and weaknesses of processes with improved transparency.In your view, are there any important limitations that must be considered?Technology evolution is happening at an enormously fast pace. As pharmaceutical manufacturing is governed by a set of compliance rules the adoption of technology takes time.You can’t adopt rapid changes in technology because the industry must go through phases of testing, adaptability, efficiency and productivity. By the time they are complete, five years may have already elapsed. Trying to keep up with the pace of technology development is becoming tough.Regulatory bodies and the pharmaceutical service industry need to collaborate regarding the regulations that become the baseline for technology development. This should allow for faster technology adoption for pharmaceutical companies.What are your thoughts on current penalties for facilities that don’t comply with regulations?Patient safety in drug manufacturing is the absolute top priority. There cannot be any compromise. Regulatory bodies are doing everything in their power to ensure that this is the case. If this is managed by imposing penalties, stopping production, recalling products or even questioning manufacturers they have the authority to decide what’s right to protect patients.However, the methods used to ensure that companies meet the regulation are at the discretion of the manufacturer. For inspections, they could adopt optical inspection using cameras or non-optical methods that use infrared ultrasound – to check the structure of drugs. Regardless of the approach they take, frequent checks and balances will always be their biggest responsibility. Quality checks at all stages of the process from raw material, batch mixing, API production, to the manufacture of the final finished tablet or capsule must be consistent. But the quality assurance process doesn’t stop there, companies must also invest time into evaluating blister packaging and bottles, label print quality, boxing, packing and shipping.Managing all these aspects of the manufacturing process can be quite intense, but technology can help in streamlining it. If companies choose to embrace the obvious benefits of digital inspections, they will certainly be able to better support patients worldwide.Source: https://pharmafile.com/news/virtual-inspections-embracing-the-digital-change/
Read more
Adding a new chapter to the history of capsule-based drug delivery
For more than 100 years, capsules have consisted of two pieces (a body and a cap). Nutritional or pharmaceutical ingredients are dosed into the body and the cap is then placed over the mouth and snapped shut. Now, however, next-generation technology is bringing a new dimension to this popular oral solid dosage form.Dr Kevin Robinson (KSR) recently caught up with Tobie Louw (TL), Vice President of Operations at Vantage Nutrition (An ACG Group Company), to discuss the market introduction of a new dietary supplement format called “Sidebysides”, brought about by the invention of the world’s first three-piece capsule, and to discover how they came to be.“The oral capsule has for more than 100 hundred years been the most effective and efficient way to bring the widest range of fixed-dose oral health solutions to market. There continues to be significant new investment in its ongoing evolution to assist with human health endeavours. This is the latest chapter in its rich history,” says Tobie.“Sidebysides” are the world’s first side by side separated oral dose health products for nutraceuticals and pharmaceuticals,” he says, “that have been created by the invention of a new three-piece capsule.”The third piece is the inventive introduction of a cup-shaped divider membrane inside a standard off-the-shelf capsule — made from the same material as the capsule — that acts as a divider inside the body of the capsule.""This enables wet and dry ingredients or incompatible actives to be housed side by side — together but separate in one product. “Sidebyside dietary supplements are rapidly gathering momentum since being launched in a vegetarian capsule format in 2020,” he adds.ComboCap, the technology-based start-up that invented and commercialised Sidebyside technology and products during the past 10 years, has developed and received 80 international patent awards for Sidebysides.The company designed, optimised and produced the unique Sidebyside technology and manufacturing process as well as the machines used to currently produce Sidebyside dietary supplements exclusively in their own world-first Sidebyside plant in New Jersey, US. ACG acquired ComboCap in early 2023.ACG is known for its enabling innovation and technology in the dietary supplement and pharmaceutical spaces.Discussing the manufacturing process, Tobie explains that a completely new type of encapsulation machine technology and process is used to produce Sidebyside products. “A Sidebyside machine takes an empty off-the-shelf hard capsule, removes the cap, doses the liquid and then inserts and seals the membrane into place. The cap is then replaced,” he says.“In the second stage of the process, the powder encapsulation takes place; the cap is removed, the powder dosed and the cap put back on — completing a Sidebyside product. This innovative technology is being extended to enable multiphase dosing on one single Sidebyside machine.”Groundbreaking technologyKey benefits for the greater life sciences industries include the fact that the three-piece Sidebyside form factor maximises the dose volumes on both sides of the membrane. It also enables customised dose sizes because the membrane position within the capsule is movable. Transparent capsules are used so that the contents of both chambers are fully visible.“The Sidebyside product format provides an ideal way to combine generally sensitive ingredients, such as probiotics, with other incompatible nutrients and actives,” adds Tobie.The dual-phase capsule-in-a-capsule has, of course, existed in the market for some time. In a cap-in-cap, a small capsule containing a powder dose is placed inside a larger one containing a liquid dose. This form factor results in the outer liquid capsule and dose being dissolved before the inner powder capsule and dose are. “With Sidebysides, the capsule shell of both chambers dissolve at the same time, enabling the ingredients to disperse and work together simultaneously; this delivers benefits such as the better absorption of key nutrients in the presence of oils.”The future rollout programme for Sidebyside products includes a number of features that cover the delayed release of the whole capsule and the release of the two independent chambers at different stages.“Delayed release is relevant because there is a significant market demand for health products that dissolve later in the digestive tract, or require a dual-stage instant beneficial effect followed by a gradual sustained one. An example of the latter is an oral health product that assists with falling asleep followed by staying asleep,” notes Tobie. KSR: What is the movable membrane and what is its function? TL: The membrane acts as a barrier between the two ingredients. It can be located in the optimum position, allowing the manufacturer to size the doses and the chambers accordingly — such as when one of the two ingredients requires a larger dose than the other.KSR: How do Sidebyside products differ from capsule-in-capsule products?TL: With Sidebysides, the separate ingredients operate together after ingestion; the chambers dissolve together. With cap-in-cap products, the separated ingredients dissolve sequentially. There are application needs for the sequential dissolution dynamic, especially when the inner chamber is required for late release.The Sidebyside product format and technology can however enable both parallel or sequential release, and can discharge either chamber ahead of the other depending on the need.Often, Sidebyside products can help to solve incompatibilities; examples include when ingredients haven’t previously been able to be combined or in the general case of needing to pair liquid and powder nutrients.By housing them with a dividing membrane, it’s possible to retain the identity and efficiency of the separated doses that may otherwise have been compromised if they had been combined and started reacting together sooner. This plays a role in enhanced product stability and shelf-life.When it comes to capsule-in-capsule products, the outer oil protects the inner capsule after ingestion and the powder is thereafter released for digestion. The oil helps to function as a delayed release solution. With Sidebysides, the use of clear capsules brings an added benefit in that a consumer has full side by side visibility of both separated ingredients in the capsule.This transparency can help to enhance patient trust ion the product and co-use buy-in and compliance. Product communication and marketing is also facilitated when references can be made to the separated contents.KSR: Can you expand on some of the enhanced combinations and what they can achieve? TL: Sidebyside products launched by brand companies to date have covered the following applications: general vitality, immunity, prenatal, woman’s health, men’s health, thyroid, sleep, calm, weight management and others.Select pharmaceutical Sidebyside applications are also being considered. One example is VASCEPA (icosapent ethyl) a pharmaceutical-grade fish oil. Published research by Amarin shows that VASCEPA DHA, when co-used with statins, brings patients a substantial enhancement in the benefits of the statin.Bringing a single two-in-one Sidebyside “VASVEPA-STAT” product to market would ensure co-use and give the combination solution in a more convenient single product format.KSR: Where next for this technology? TL: We are currently exploring a number of exciting controlled released options. This includes bringing single-stage, two-stage and triple-delayed release Sidebysides to market.Triple-delayed release Sidebysides can utilise a number of ingredient formats including liquids, powders and beadlets, whereby a mix of delayed-release beadlets is used to achieve the second and third stage release after the early stage release of the liquid dose.We are also progressing the development of beadlet-liquid and powder-powder and liquid-liquid Sidebyside health products. To date, no commercially available separated powder-powder oral health dose product exists in the market … and they have not been possible in existing capsule formats.In addition, we’re looking at developing the science behind exciting combinations such as prebiotic/probiotic Sidebysides in powder-powder form.By continuing to invest, extend, and bring to market the latest, most effective and efficient capsule technologies and innovative oral-dose health products, ACG continues to build its lead innovator status as a global top tier capsule company.Source: https://manufacturingchemist.com/
Read more
ACG acquires specialty packaging foils supplier
ACG strengthened its packaging solutions services by acquiring Technical Aluminum Foil Company.Capsules and packaging manufacturer ACG (Mumbai, India) has acquired specialty packaging foils supplier Technical Aluminum Foil Company (TAFC; Ajman, United Arab Emirates). ACG says this acquisition strengthens its comprehensive packaging solutions, especially in the Middle Eastern and African markets.TAFC’s aluminum and specialty packaging have high barrier properties and are used in both the pharmaceutical and food industries. The company also specializes in lacquering, lamination, printing, and slitting services.Source: https://www.nutritionaloutlook.com/
Read more
Improving Machinery in Pharmaceutical Manufacturing
IPT talks to Richard Stedman of ACG Engineering about the rise of connected and digitalised machines, and how these will improve pharmaceutical manufacturing in the futureIPT: Which pharmaceutical manufacturing innovation has had the most significant effect?Richard Stedman (RS): I have been a consumer of pharmaceuticals for a great deal longer than I have been on the manufacturing side of the industry. I therefore greatly value innovations that make the life of the patient easier – those which help to reduce any suffering.I believe that innovations such as fixed dosage combinations and modified release pills have been inspirational in terms of combatting patient reluctance around consuming multiple dosages.IPT: What are ‘connected machines’ and how has their rise benefited pharmaceutical manufacturing?RS: Connected machines focus on holistically improving total cost of ownership (TCO) through optimising equipment efficiency and performance. Numerous sensors collect data across various aspects, including the production process, overall energy consumption, maintenance and machine health. This combined information helps subject matter experts (technicians) to build curated dashboards to enable pharma manufacturers to effectively monitor their equipment. This, in turn, helps them to identify opportunities and adjust the process, improve productivity, reduce downtime and eliminate unnecessary energy consumption.The goal of such machines is to help manufacturers maintain the processes of the equipment at optimum levels, helping to maximise overall productivity and, in doing so, improve TCO.IPT: What are some of the most important aspects to consider when collaborating with other countries for equipment design?RS: Firstly, process and communication are crucial. Clear and effective communication channels must be established, taking factors such as language barriers, cultural differences and time zones into consideration. Regular video conferences and meetings, emails and documentation exchange are all essential for successful collaboration. The process of collaboration must be clearly defined.Secondly, understanding the regulatory requirements of the target country is vital. It’s important to have an appreciation of the fact that each country may have different standards and regulations for equipment design in the pharmaceutical industry. Compliance with these regulations is essential to ensure the safety, quality and efficacy of the final product.Thirdly, intellectual property (IP) protection must be evaluated. Collaborating with other countries may involve sharing sensitive information and designs. Robust contracts, including non-disclosure agreements (NDAs) and intellectual property protection measures, should be in place to safeguard proprietary information and the end user.Fourth, technical expertise is critical. Collaborating with partners who have the necessary technical knowledge and experience in the pharmaceutical industry is paramount when it comes to designing high-quality and efficient equipment.Lastly, cultural understanding and mutual respect are important. Being aware of cultural differences, customs and business practices can foster a positive and productive working relationship with international partners.In conclusion, successful collaboration for equipment design with other countries requires effective communication, defined processes, understanding of regulatory requirements, IP protection, technical expertise and cultural awareness.IPT: How are developments in pharmaceutical machines enabling tabletting and capsuling devices to maintain high standards of production?RS: As has always been the ethos of the pharma industry, which underlies the cGMP (current Good Manufacturing Practices), quality remains of utmost importance. Every enhancement of the quality and OEE (overall equipment effectiveness) in pharma manufacturing means more lives made better. Significant advancements in pharmaceutical machines have enabled tabletting and capsuling devices to maintain the highest standards of production. Such developments have been instrumental in improving the efficiency, precision and quality of tablet and capsule production across the industry.One key development is the integration of automation in pharmaceutical machines. Automation has revolutionised the manufacturing process by reducing human intervention, thereby minimising the risk of errors and contamination. Automatic systems have been incorporated into tabletting and capsuling devices, allowing for precise and consistent dosing, filling and sealing of tablets and capsules. This has resulted in higher production rates and improved product quality, as automatic systems can consistently perform repetitive tasks with minimal variation.Another significant advancement is the use of cutting-edge sensors and monitoring systems. These sensors provide real-time data on critical process parameters such as temperature, pressure and humidity, allowing for precise control and monitoring of the manufacturing process. This ensures that tablets and capsules are produced within the specified tolerances, maintaining high standards of quality and consistency.Advancements in material handling and feeding systems have also contributed to maintaining high standards of production. These ensure that the right amount of raw materials is accurately measured, mixed and fed into the machines, resulting in uniformity in both the composition and weight of tablets and capsules.Additionally, improvements in machine design and construction have led to machines that are more hygienic and easier to clean, reducing the risk of cross-contamination and ensuring compliance with the industry’s strict regulatory requirements.Developments in pharmaceutical machines, including automation, advanced sensors and monitoring systems, material handling and feeding systems and improved machine design, have resulted in increased efficiency, precision and quality in the manufacture of tablets and capsules. As a result, this has hugely benefited the pharmaceutical industry and, ultimately, the patients who rely on these medications for their health and well-being.IPT: Where do you see the developments in pharmaceutical machine manufacturing heading in the next decade?RS: I believe the future of pharmaceutical machine manufacturing will be characterised by a number of significant advancements and innovations.First and foremost, automation and digitisation will continue to play a crucial role in the pharmaceutical machine manufacturing industry. We will witness the integration of cutting-edge technologies, such as artificial intelligence (AI), machine learning (ML) and the Internet of Things (IoT), into pharmaceutical machines to enhance their efficiency and precision. This will result in increased productivity, reduced downtime and improved quality control, leading to higher yields and cost savings for pharmaceutical manufacturers and the lowering of TCO.Moreover, there will be a growing emphasis on sustainability and environmental consciousness over the next decade. Pharmaceutical machine manufacturers will focus on developing eco-friendly machines that minimise waste, reduce energy consumption and comply with stringent environmental regulations. This will involve the use of renewable energy sources, the implementation of green manufacturing practices and the adoption of recyclable and biodegradable materials across machine components.Furthermore, the trend towards personalised medicine and customised pharmaceutical products will impact pharmaceutical machine manufacturing. Machines that can handle smaller batches, accommodate varying formulations and enable rapid changeovers will be in high demand. Manufacturers will need to be flexibile and adaptable in order to meet the evolving needs of the pharmaceutical industry.Regulatory compliance will continue to be a top priority in pharmaceutical machine manufacturing. Stringent regulations governing the production of pharmaceuticals, including tablets and capsules, will drive the development of machines that ensure compliance with good manufacturing practices (GMP), international standards and regulatory guidelines. This will involve robust documentation, validation and qualification processes to ensure the safety, efficacy and quality of pharmaceutical products.In summary, the developments in pharmaceutical machine manufacturing in the next decade will be characterised by automation, digitisation, sustainability, customisation and regulatory compliance. The industry will witness the integration of advanced technologieIPT talks to Richard Stedman of ACG Engineering about the rise of connected and digitalised machines, and how these will improve pharmaceutical manufacturing in the futureIPT: Which pharmaceutical manufacturing innovation has had the most significant effect?Richard Stedman (RS): I have been a consumer of pharmaceuticals for a great deal longer than I have been on the manufacturing side of the industry. I therefore greatly value innovations that make the life of the patient easier – those which help to reduce any suffering.I believe that innovations such as fixed dosage combinations and modified release pills have been inspirational in terms of combatting patient reluctance around consuming multiple dosages.IPT: What are ‘connected machines’ and how has their rise benefited pharmaceutical manufacturing?RS: Connected machines focus on holistically improving total cost of ownership (TCO) through optimising equipment efficiency and performance. Numerous sensors collect data across various aspects, including the production process, overall energy consumption, maintenance and machine health. This combined information helps subject matter experts (technicians) to build curated dashboards to enable pharma manufacturers to effectively monitor their equipment. This, in turn, helps them to identify opportunities and adjust the process, improve productivity, reduce downtime and eliminate unnecessary energy consumption.The goal of such machines is to help manufacturers maintain the processes of the equipment at optimum levels, helping to maximise overall productivity and, in doing so, improve TCO.IPT: What are some of the most important aspects to consider when collaborating with other countries for equipment design?RS: Firstly, process and communication are crucial. Clear and effective communication channels must be established, taking factors such as language barriers, cultural differences and time zones into consideration. Regular video conferences and meetings, emails and documentation exchange are all essential for successful collaboration. The process of collaboration must be clearly defined.Secondly, understanding the regulatory requirements of the target country is vital. It’s important to have an appreciation of the fact that each country may have different standards and regulations for equipment design in the pharmaceutical industry. Compliance with these regulations is essential to ensure the safety, quality and efficacy of the final product.Thirdly, intellectual property (IP) protection must be evaluated. Collaborating with other countries may involve sharing sensitive information and designs. Robust contracts, including non-disclosure agreements (NDAs) and intellectual property protection measures, should be in place to safeguard proprietary information and the end user.Fourth, technical expertise is critical. Collaborating with partners who have the necessary technical knowledge and experience in the pharmaceutical industry is paramount when it comes to designing high-quality and efficient equipment.Lastly, cultural understanding and mutual respect are important. Being aware of cultural differences, customs and business practices can foster a positive and productive working relationship with international partners.In conclusion, successful collaboration for equipment design with other countries requires effective communication, defined processes, understanding of regulatory requirements, IP protection, technical expertise and cultural awareness.IPT: How are developments in pharmaceutical machines enabling tabletting and capsuling devices to maintain high standards of production?RS: As has always been the ethos of the pharma industry, which underlies the cGMP (current Good Manufacturing Practices), quality remains of utmost importance. Every enhancement of the quality and OEE (overall equipment effectiveness) in pharma manufacturing means more lives made better. Significant advancements in pharmaceutical machines have enabled tabletting and capsuling devices to maintain the highest standards of production. Such developments have been instrumental in improving the efficiency, precision and quality of tablet and capsule production across the industry.One key development is the integration of automation in pharmaceutical machines. Automation has revolutionised the manufacturing process by reducing human intervention, thereby minimising the risk of errors and contamination. Automatic systems have been incorporated into tabletting and capsuling devices, allowing for precise and consistent dosing, filling and sealing of tablets and capsules. This has resulted in higher production rates and improved product quality, as automatic systems can consistently perform repetitive tasks with minimal variation.Another significant advancement is the use of cutting-edge sensors and monitoring systems. These sensors provide real-time data on critical process parameters such as temperature, pressure and humidity, allowing for precise control and monitoring of the manufacturing process. This ensures that tablets and capsules are produced within the specified tolerances, maintaining high standards of quality and consistency.Advancements in material handling and feeding systems have also contributed to maintaining high standards of production. These ensure that the right amount of raw materials is accurately measured, mixed and fed into the machines, resulting in uniformity in both the composition and weight of tablets and capsules.Additionally, improvements in machine design and construction have led to machines that are more hygienic and easier to clean, reducing the risk of cross-contamination and ensuring compliance with the industry’s strict regulatory requirements.Developments in pharmaceutical machines, including automation, advanced sensors and monitoring systems, material handling and feeding systems and improved machine design, have resulted in increased efficiency, precision and quality in the manufacture of tablets and capsules. As a result, this has hugely benefited the pharmaceutical industry and, ultimately, the patients who rely on these medications for their health and well-being.IPT: Where do you see the developments in pharmaceutical machine manufacturing heading in the next decade?RS: I believe the future of pharmaceutical machine manufacturing will be characterised by a number of significant advancements and innovations.First and foremost, automation and digitisation will continue to play a crucial role in the pharmaceutical machine manufacturing industry. We will witness the integration of cutting-edge technologies, such as artificial intelligence (AI), machine learning (ML) and the Internet of Things (IoT), into pharmaceutical machines to enhance their efficiency and precision. This will result in increased productivity, reduced downtime and improved quality control, leading to higher yields and cost savings for pharmaceutical manufacturers and the lowering of TCO.Moreover, there will be a growing emphasis on sustainability and environmental consciousness over the next decade. Pharmaceutical machine manufacturers will focus on developing eco-friendly machines that minimise waste, reduce energy consumption and comply with stringent environmental regulations. This will involve the use of renewable energy sources, the implementation of green manufacturing practices and the adoption of recyclable and biodegradable materials across machine components.Furthermore, the trend towards personalised medicine and customised pharmaceutical products will impact pharmaceutical machine manufacturing. Machines that can handle smaller batches, accommodate varying formulations and enable rapid changeovers will be in high demand. Manufacturers will need to be flexibile and adaptable in order to meet the evolving needs of the pharmaceutical industry.Regulatory compliance will continue to be a top priority in pharmaceutical machine manufacturing. Stringent regulations governing the production of pharmaceuticals, including tablets and capsules, will drive the development of machines that ensure compliance with good manufacturing practices (GMP), international standards and regulatory guidelines. This will involve robust documentation, validation and qualification processes to ensure the safety, efficacy and quality of pharmaceutical products.In summary, the developments in pharmaceutical machine manufacturing in the next decade will be characterised by automation, digitisation, sustainability, customisation and regulatory compliance. The industry will witness the integration of advanced technologieIPT talks to Richard Stedman of ACG Engineering about the rise of connected and digitalised machines, and how these will improve pharmaceutical manufacturing in the futureIPT: Which pharmaceutical manufacturing innovation has had the most significant effect?Richard Stedman (RS): I have been a consumer of pharmaceuticals for a great deal longer than I have been on the manufacturing side of the industry. I therefore greatly value innovations that make the life of the patient easier – those which help to reduce any suffering.I believe that innovations such as fixed dosage combinations and modified release pills have been inspirational in terms of combatting patient reluctance around consuming multiple dosages.IPT: What are ‘connected machines’ and how has their rise benefited pharmaceutical manufacturing?RS: Connected machines focus on holistically improving total cost of ownership (TCO) through optimising equipment efficiency and performance. Numerous sensors collect data across various aspects, including the production process, overall energy consumption, maintenance and machine health. This combined information helps subject matter experts (technicians) to build curated dashboards to enable pharma manufacturers to effectively monitor their equipment. This, in turn, helps them to identify opportunities and adjust the process, improve productivity, reduce downtime and eliminate unnecessary energy consumption.The goal of such machines is to help manufacturers maintain the processes of the equipment at optimum levels, helping to maximise overall productivity and, in doing so, improve TCO.IPT: What are some of the most important aspects to consider when collaborating with other countries for equipment design?RS: Firstly, process and communication are crucial. Clear and effective communication channels must be established, taking factors such as language barriers, cultural differences and time zones into consideration. Regular video conferences and meetings, emails and documentation exchange are all essential for successful collaboration. The process of collaboration must be clearly defined.Secondly, understanding the regulatory requirements of the target country is vital. It’s important to have an appreciation of the fact that each country may have different standards and regulations for equipment design in the pharmaceutical industry. Compliance with these regulations is essential to ensure the safety, quality and efficacy of the final product.Thirdly, intellectual property (IP) protection must be evaluated. Collaborating with other countries may involve sharing sensitive information and designs. Robust contracts, including non-disclosure agreements (NDAs) and intellectual property protection measures, should be in place to safeguard proprietary information and the end user.Fourth, technical expertise is critical. Collaborating with partners who have the necessary technical knowledge and experience in the pharmaceutical industry is paramount when it comes to designing high-quality and efficient equipment.Lastly, cultural understanding and mutual respect are important. Being aware of cultural differences, customs and business practices can foster a positive and productive working relationship with international partners.In conclusion, successful collaboration for equipment design with other countries requires effective communication, defined processes, understanding of regulatory requirements, IP protection, technical expertise and cultural awareness.IPT: How are developments in pharmaceutical machines enabling tabletting and capsuling devices to maintain high standards of production?RS: As has always been the ethos of the pharma industry, which underlies the cGMP (current Good Manufacturing Practices), quality remains of utmost importance. Every enhancement of the quality and OEE (overall equipment effectiveness) in pharma manufacturing means more lives made better. Significant advancements in pharmaceutical machines have enabled tabletting and capsuling devices to maintain the highest standards of production. Such developments have been instrumental in improving the efficiency, precision and quality of tablet and capsule production across the industry.One key development is the integration of automation in pharmaceutical machines. Automation has revolutionised the manufacturing process by reducing human intervention, thereby minimising the risk of errors and contamination. Automatic systems have been incorporated into tabletting and capsuling devices, allowing for precise and consistent dosing, filling and sealing of tablets and capsules. This has resulted in higher production rates and improved product quality, as automatic systems can consistently perform repetitive tasks with minimal variation.Another significant advancement is the use of cutting-edge sensors and monitoring systems. These sensors provide real-time data on critical process parameters such as temperature, pressure and humidity, allowing for precise control and monitoring of the manufacturing process. This ensures that tablets and capsules are produced within the specified tolerances, maintaining high standards of quality and consistency.Advancements in material handling and feeding systems have also contributed to maintaining high standards of production. These ensure that the right amount of raw materials is accurately measured, mixed and fed into the machines, resulting in uniformity in both the composition and weight of tablets and capsules.Additionally, improvements in machine design and construction have led to machines that are more hygienic and easier to clean, reducing the risk of cross-contamination and ensuring compliance with the industry’s strict regulatory requirements.Developments in pharmaceutical machines, including automation, advanced sensors and monitoring systems, material handling and feeding systems and improved machine design, have resulted in increased efficiency, precision and quality in the manufacture of tablets and capsules. As a result, this has hugely benefited the pharmaceutical industry and, ultimately, the patients who rely on these medications for their health and well-being.IPT: Where do you see the developments in pharmaceutical machine manufacturing heading in the next decade?RS: I believe the future of pharmaceutical machine manufacturing will be characterised by a number of significant advancements and innovations.First and foremost, automation and digitisation will continue to play a crucial role in the pharmaceutical machine manufacturing industry. We will witness the integration of cutting-edge technologies, such as artificial intelligence (AI), machine learning (ML) and the Internet of Things (IoT), into pharmaceutical machines to enhance their efficiency and precision. This will result in increased productivity, reduced downtime and improved quality control, leading to higher yields and cost savings for pharmaceutical manufacturers and the lowering of TCO.Moreover, there will be a growing emphasis on sustainability and environmental consciousness over the next decade. Pharmaceutical machine manufacturers will focus on developing eco-friendly machines that minimise waste, reduce energy consumption and comply with stringent environmental regulations. This will involve the use of renewable energy sources, the implementation of green manufacturing practices and the adoption of recyclable and biodegradable materials across machine components.Furthermore, the trend towards personalised medicine and customised pharmaceutical products will impact pharmaceutical machine manufacturing. Machines that can handle smaller batches, accommodate varying formulations and enable rapid changeovers will be in high demand. Manufacturers will need to be flexibile and adaptable in order to meet the evolving needs of the pharmaceutical industry.Regulatory compliance will continue to be a top priority in pharmaceutical machine manufacturing. Stringent regulations governing the production of pharmaceuticals, including tablets and capsules, will drive the development of machines that ensure compliance with good manufacturing practices (GMP), international standards and regulatory guidelines. This will involve robust documentation, validation and qualification processes to ensure the safety, efficacy and quality of pharmaceutical products.In summary, the developments in pharmaceutical machine manufacturing in the next decade will be characterised by automation, digitisation, sustainability, customisation and regulatory compliance. The industry will witness the integration of advanced technologieIPT talks to Richard Stedman of ACG Engineering about the rise of connected and digitalised machines, and how these will improve pharmaceutical manufacturing in the futureIPT: Which pharmaceutical manufacturing innovation has had the most significant effect?Richard Stedman (RS): I have been a consumer of pharmaceuticals for a great deal longer than I have been on the manufacturing side of the industry. I therefore greatly value innovations that make the life of the patient easier – those which help to reduce any suffering.I believe that innovations such as fixed dosage combinations and modified release pills have been inspirational in terms of combatting patient reluctance around consuming multiple dosages.IPT: What are ‘connected machines’ and how has their rise benefited pharmaceutical manufacturing?RS: Connected machines focus on holistically improving total cost of ownership (TCO) through optimising equipment efficiency and performance. Numerous sensors collect data across various aspects, including the production process, overall energy consumption, maintenance and machine health. This combined information helps subject matter experts (technicians) to build curated dashboards to enable pharma manufacturers to effectively monitor their equipment. This, in turn, helps them to identify opportunities and adjust the process, improve productivity, reduce downtime and eliminate unnecessary energy consumption.The goal of such machines is to help manufacturers maintain the processes of the equipment at optimum levels, helping to maximise overall productivity and, in doing so, improve TCO.IPT: What are some of the most important aspects to consider when collaborating with other countries for equipment design?RS: Firstly, process and communication are crucial. Clear and effective communication channels must be established, taking factors such as language barriers, cultural differences and time zones into consideration. Regular video conferences and meetings, emails and documentation exchange are all essential for successful collaboration. The process of collaboration must be clearly defined.Secondly, understanding the regulatory requirements of the target country is vital. It’s important to have an appreciation of the fact that each country may have different standards and regulations for equipment design in the pharmaceutical industry. Compliance with these regulations is essential to ensure the safety, quality and efficacy of the final product.Thirdly, intellectual property (IP) protection must be evaluated. Collaborating with other countries may involve sharing sensitive information and designs. Robust contracts, including non-disclosure agreements (NDAs) and intellectual property protection measures, should be in place to safeguard proprietary information and the end user.Fourth, technical expertise is critical. Collaborating with partners who have the necessary technical knowledge and experience in the pharmaceutical industry is paramount when it comes to designing high-quality and efficient equipment.Lastly, cultural understanding and mutual respect are important. Being aware of cultural differences, customs and business practices can foster a positive and productive working relationship with international partners.In conclusion, successful collaboration for equipment design with other countries requires effective communication, defined processes, understanding of regulatory requirements, IP protection, technical expertise and cultural awareness.IPT: How are developments in pharmaceutical machines enabling tabletting and capsuling devices to maintain high standards of production?RS: As has always been the ethos of the pharma industry, which underlies the cGMP (current Good Manufacturing Practices), quality remains of utmost importance. Every enhancement of the quality and OEE (overall equipment effectiveness) in pharma manufacturing means more lives made better. Significant advancements in pharmaceutical machines have enabled tabletting and capsuling devices to maintain the highest standards of production. Such developments have been instrumental in improving the efficiency, precision and quality of tablet and capsule production across the industry.One key development is the integration of automation in pharmaceutical machines. Automation has revolutionised the manufacturing process by reducing human intervention, thereby minimising the risk of errors and contamination. Automatic systems have been incorporated into tabletting and capsuling devices, allowing for precise and consistent dosing, filling and sealing of tablets and capsules. This has resulted in higher production rates and improved product quality, as automatic systems can consistently perform repetitive tasks with minimal variation.Another significant advancement is the use of cutting-edge sensors and monitoring systems. These sensors provide real-time data on critical process parameters such as temperature, pressure and humidity, allowing for precise control and monitoring of the manufacturing process. This ensures that tablets and capsules are produced within the specified tolerances, maintaining high standards of quality and consistency.Advancements in material handling and feeding systems have also contributed to maintaining high standards of production. These ensure that the right amount of raw materials is accurately measured, mixed and fed into the machines, resulting in uniformity in both the composition and weight of tablets and capsules.Additionally, improvements in machine design and construction have led to machines that are more hygienic and easier to clean, reducing the risk of cross-contamination and ensuring compliance with the industry’s strict regulatory requirements.Developments in pharmaceutical machines, including automation, advanced sensors and monitoring systems, material handling and feeding systems and improved machine design, have resulted in increased efficiency, precision and quality in the manufacture of tablets and capsules. As a result, this has hugely benefited the pharmaceutical industry and, ultimately, the patients who rely on these medications for their health and well-being.IPT: Where do you see the developments in pharmaceutical machine manufacturing heading in the next decade?RS: I believe the future of pharmaceutical machine manufacturing will be characterised by a number of significant advancements and innovations.First and foremost, automation and digitisation will continue to play a crucial role in the pharmaceutical machine manufacturing industry. We will witness the integration of cutting-edge technologies, such as artificial intelligence (AI), machine learning (ML) and the Internet of Things (IoT), into pharmaceutical machines to enhance their efficiency and precision. This will result in increased productivity, reduced downtime and improved quality control, leading to higher yields and cost savings for pharmaceutical manufacturers and the lowering of TCO.Moreover, there will be a growing emphasis on sustainability and environmental consciousness over the next decade. Pharmaceutical machine manufacturers will focus on developing eco-friendly machines that minimise waste, reduce energy consumption and comply with stringent environmental regulations. This will involve the use of renewable energy sources, the implementation of green manufacturing practices and the adoption of recyclable and biodegradable materials across machine components.Furthermore, the trend towards personalised medicine and customised pharmaceutical products will impact pharmaceutical machine manufacturing. Machines that can handle smaller batches, accommodate varying formulations and enable rapid changeovers will be in high demand. Manufacturers will need to be flexibile and adaptable in order to meet the evolving needs of the pharmaceutical industry.Regulatory compliance will continue to be a top priority in pharmaceutical machine manufacturing. Stringent regulations governing the production of pharmaceuticals, including tablets and capsules, will drive the development of machines that ensure compliance with good manufacturing practices (GMP), international standards and regulatory guidelines. This will involve robust documentation, validation and qualification processes to ensure the safety, efficacy and quality of pharmaceutical products.In summary, the developments in pharmaceutical machine manufacturing in the next decade will be characterised by automation, digitisation, sustainability, customisation and regulatory compliance. The industry will witness the integration of advanced technologieIPT talks to Richard Stedman of ACG Engineering about the rise of connected and digitalised machines, and how these will improve pharmaceutical manufacturing in the futureIPT: Which pharmaceutical manufacturing innovation has had the most significant effect?Richard Stedman (RS): I have been a consumer of pharmaceuticals for a great deal longer than I have been on the manufacturing side of the industry. I therefore greatly value innovations that make the life of the patient easier – those which help to reduce any suffering.I believe that innovations such as fixed dosage combinations and modified release pills have been inspirational in terms of combatting patient reluctance around consuming multiple dosages.IPT: What are ‘connected machines’ and how has their rise benefited pharmaceutical manufacturing?RS: Connected machines focus on holistically improving total cost of ownership (TCO) through optimising equipment efficiency and performance. Numerous sensors collect data across various aspects, including the production process, overall energy consumption, maintenance and machine health. This combined information helps subject matter experts (technicians) to build curated dashboards to enable pharma manufacturers to effectively monitor their equipment. This, in turn, helps them to identify opportunities and adjust the process, improve productivity, reduce downtime and eliminate unnecessary energy consumption.The goal of such machines is to help manufacturers maintain the processes of the equipment at optimum levels, helping to maximise overall productivity and, in doing so, improve TCO.IPT: What are some of the most important aspects to consider when collaborating with other countries for equipment design?RS: Firstly, process and communication are crucial. Clear and effective communication channels must be established, taking factors such as language barriers, cultural differences and time zones into consideration. Regular video conferences and meetings, emails and documentation exchange are all essential for successful collaboration. The process of collaboration must be clearly defined.Secondly, understanding the regulatory requirements of the target country is vital. It’s important to have an appreciation of the fact that each country may have different standards and regulations for equipment design in the pharmaceutical industry. Compliance with these regulations is essential to ensure the safety, quality and efficacy of the final product.Thirdly, intellectual property (IP) protection must be evaluated. Collaborating with other countries may involve sharing sensitive information and designs. Robust contracts, including non-disclosure agreements (NDAs) and intellectual property protection measures, should be in place to safeguard proprietary information and the end user.Fourth, technical expertise is critical. Collaborating with partners who have the necessary technical knowledge and experience in the pharmaceutical industry is paramount when it comes to designing high-quality and efficient equipment.Lastly, cultural understanding and mutual respect are important. Being aware of cultural differences, customs and business practices can foster a positive and productive working relationship with international partners.In conclusion, successful collaboration for equipment design with other countries requires effective communication, defined processes, understanding of regulatory requirements, IP protection, technical expertise and cultural awareness.IPT: How are developments in pharmaceutical machines enabling tabletting and capsuling devices to maintain high standards of production?RS: As has always been the ethos of the pharma industry, which underlies the cGMP (current Good Manufacturing Practices), quality remains of utmost importance. Every enhancement of the quality and OEE (overall equipment effectiveness) in pharma manufacturing means more lives made better. Significant advancements in pharmaceutical machines have enabled tabletting and capsuling devices to maintain the highest standards of production. Such developments have been instrumental in improving the efficiency, precision and quality of tablet and capsule production across the industry.One key development is the integration of automation in pharmaceutical machines. Automation has revolutionised the manufacturing process by reducing human intervention, thereby minimising the risk of errors and contamination. Automatic systems have been incorporated into tabletting and capsuling devices, allowing for precise and consistent dosing, filling and sealing of tablets and capsules. This has resulted in higher production rates and improved product quality, as automatic systems can consistently perform repetitive tasks with minimal variation.Another significant advancement is the use of cutting-edge sensors and monitoring systems. These sensors provide real-time data on critical process parameters such as temperature, pressure and humidity, allowing for precise control and monitoring of the manufacturing process. This ensures that tablets and capsules are produced within the specified tolerances, maintaining high standards of quality and consistency.Advancements in material handling and feeding systems have also contributed to maintaining high standards of production. These ensure that the right amount of raw materials is accurately measured, mixed and fed into the machines, resulting in uniformity in both the composition and weight of tablets and capsules.Additionally, improvements in machine design and construction have led to machines that are more hygienic and easier to clean, reducing the risk of cross-contamination and ensuring compliance with the industry’s strict regulatory requirements.Developments in pharmaceutical machines, including automation, advanced sensors and monitoring systems, material handling and feeding systems and improved machine design, have resulted in increased efficiency, precision and quality in the manufacture of tablets and capsules. As a result, this has hugely benefited the pharmaceutical industry and, ultimately, the patients who rely on these medications for their health and well-being.IPT: Where do you see the developments in pharmaceutical machine manufacturing heading in the next decade?RS: I believe the future of pharmaceutical machine manufacturing will be characterised by a number of significant advancements and innovations.First and foremost, automation and digitisation will continue to play a crucial role in the pharmaceutical machine manufacturing industry. We will witness the integration of cutting-edge technologies, such as artificial intelligence (AI), machine learning (ML) and the Internet of Things (IoT), into pharmaceutical machines to enhance their efficiency and precision. This will result in increased productivity, reduced downtime and improved quality control, leading to higher yields and cost savings for pharmaceutical manufacturers and the lowering of TCO.Moreover, there will be a growing emphasis on sustainability and environmental consciousness over the next decade. Pharmaceutical machine manufacturers will focus on developing eco-friendly machines that minimise waste, reduce energy consumption and comply with stringent environmental regulations. This will involve the use of renewable energy sources, the implementation of green manufacturing practices and the adoption of recyclable and biodegradable materials across machine components.Furthermore, the trend towards personalised medicine and customised pharmaceutical products will impact pharmaceutical machine manufacturing. Machines that can handle smaller batches, accommodate varying formulations and enable rapid changeovers will be in high demand. Manufacturers will need to be flexibile and adaptable in order to meet the evolving needs of the pharmaceutical industry.Regulatory compliance will continue to be a top priority in pharmaceutical machine manufacturing. Stringent regulations governing the production of pharmaceuticals, including tablets and capsules, will drive the development of machines that ensure compliance with good manufacturing practices (GMP), international standards and regulatory guidelines. This will involve robust documentation, validation and qualification processes to ensure the safety, efficacy and quality of pharmaceutical products.In summary, the developments in pharmaceutical machine manufacturing in the next decade will be characterised by automation, digitisation, sustainability, customisation and regulatory compliance. The industry will witness the integration of advanced technologies, increased focus on environmental sustainability and the development of flexible and compliant machines to meet the industry’s evolving needs.Richard Stedman is the CEO of ACG Engineering. With over 35 years of experience in the packaging, engineering and pharmaceutical manufacturing industries, Richard has led and transformed multiple businesses globally. Richard is committed to driving innovation and excellence in the pharmaceutical manufacturing industry. He is passionate about delivering high-quality products and services to customers and is dedicated to building a strong and sustainable future for ACG.Source: https://www.iptonline.com/
Read more
As nutraceutical and pharmaceutical firms compete for a bigger slice of the healthcare market, delivery innovations like pelletization will help them stand out
How pelletization can give the nutraceutical industry a boost, according to experts from Vantage Nutrition and ACG Capsules.The level of awareness individuals have of their own health and well-being grew exponentially during the COVID-19 pandemic. This awareness fueled a shift from a reactive approach to health and personal care to a more proactive and predictive one.The nutraceutical and pharmaceutical industries are now vying for a wider share of this growing base of health-conscious individuals. This has translated to greater innovation and an expanding portfolio of high-quality and convenient products aimed at improving consumer health.The Advantages of Pelletization for Oral SupplementsThe majority of nutraceutical supplements offered are available in an oral format. New technologies continue to pave the way for innovation when it comes to release modification and new product development.Pelletization has proved to be a boon for nutraceutical providers, opening the door to a plethora of opportunities for the nutraceutical sector. It can offer suitable, cost-efficient solutions to multiple challenges, including efficacy, dosage, delivery, and absorption challenges.Typically, the pellets found in supplements are small, free-flowing spherical or semi-spherical solid particles made up of fine powders or granules which then can be coated or encapsulated with other materials. They are used primarily for release modification of active ingredients and can therefore play a role in enhancing the efficacy of a supplement.Pelletization can also provide a greater degree of flexibility with respect to the evolution and appearance of product formulations. It allows the separation of active ingredients into completely different dose strengths, without the need for method changes, and can be used to administer incompatible, biologically active substances all at once. It also offers the scope for immediate or controlled oral delivery.Additionally, pellet formations can help to improve the absorption and distribution of actives. The coating applied during pelletization forms a protective layer, helping to mask the odor and unpleasant taste of active ingredients, improving palatability. This helps to increase consumer compliance, while the aesthetic appeal of the pellets enhances the distinction of the product, which can improve marketing efforts.Emerging InnovationsThese examples of the evolution and growth of pelletization over the last decade has nutraceutical innovators looking to the future. Developers are moving beyond simple pellet formulations and are exploring all the possible options, focusing on new and more effective technologies that can help to bring purer, more effective, and more complex products to market.Traditionally, pellets have been used in product forms like sachets, capsules, and tablets. Pellets in capsules are widely accepted nowadays and offer the most scope for overall product modification, with the hard capsule acting as an excellent container to deliver the pellets to the desired site.Sprinkle capsules have recently emerged as a new trend, aimed at people who have difficulty swallowing, including children and the elderly. These capsules carry the active content in pellet form, which can be sprinkled on food or juice.Capsules that combine two separate delivery systems, like pellets and liquid formulation in a single unit, are another example of an innovation gaining momentum. One of the challenges the nutraceutical industry currently faces is how to deliver complex materials in way that enhances their effectiveness and ensures maximum absorption in an efficient manner. This novel technique can provide the means to deliver complex actives by incorporating them in their original form, whether in a liquid or a solid. They can deliver the active ingredients immediately (via liquid), and in a controlled manner (through solid pellets), simultaneously. This format also satisfies compatibility issues on an operational level by offering the choice of pellets with tiny capsules in liquid-filled capsules.The FuturePelletization is not a new technology, but it continues to be a revolutionary one when it comes to providing versatile delivery formats for nutraceuticals and pharmaceuticals alike. It has shown an immense scope for customization and modification in release patterns, as well as aesthetic appeal. With its significant potential for growth and brand extension, pelletization is set to continue providing significant benefits to manufacturers, consumers, and market players.About the AuthorsSurya Singh, PhD, is senior manager of product development at Vantage Nutrition LLP (India). Jnanadeva Bhat, PhD, is head of formulation R&D, pharma and nutra, at Vantage Nutrition LLP and ACG Capsules (India). Manali Dalvi, M.Pharm, is the lead whitepaper and publications specialist, pharma and nutra, at Vantage Nutrition LLP and ACG Capsules.Source: https://www.nutritionaloutlook.com/
Read more
Ajit Singh
Ajit Singh
Ajit Singh earned his graduation degree from Cambridge University, UK, and post-graduation degree from Harvard Business School, USA. He currently resides in Mumbai, India, and travels widely to study pharmaceutical and allied industries.
Ajit is the Chairman of the ACG Group (formerly known as the Associated Capsules Group of Companies), which is headquartered in Mumbai. He has played a prominent role in the development of the pharmaceutical and allied industries in India and has served as an executive committee member of the Federation of Indian Chambers of Commerce & Industry (FICCI), a regional council member of the Confederation of Indian Industry (CII), Western Region, and other prominent pharmaceutical associations in India. He has also been conferred with prestigious awards for his contributions and thoughtful leadership to the pharmaceutical industry.
Ajit was a founder-member of the Young Presidents’ Organization – India Chapter and the first Indian to be invited to serve on its international board in the USA.
Jasjit Singh
Jasjit Singh
Along with his brother, Ajit, Jasjit started the Associated Capsules Group in Mumbai in 1962.
Jasjit has always been interested in technology – particularly that relating to machine design – and earned a degree in Mechanical Engineering from London University. He has dozens of patents to his credit, and under his leadership the ACG Group has received numerous global awards for technology, excellence and social welfare.
Jasjit has been actively involved with starting new Forums of the Young Presidents’ Organisation. He served as the Chairman of the Mumbai Chapter, and helped found the Kolkata Chapter before becoming a founding President of the World Presidents’ Organisation. Jasjit has also received the Vijay Ratna Award for leadership in Industry, and recognition from UNIDO for his contribution to the fields of pharmaceutical technology and environmental science.
Jasjit’s other interests include self-education, reading, music, collecting rare works of arts and helping young contemporary artists, cooking, and travelling to different parts of the world – especially with his family.
Karan Singh
Karan Singh
An organisational psychologist by education, Karan has transformed ACG from a modest Indian business into a world-renowned institution, revolutionising its vision and long-term strategy to ensure global growth. Karan has overseen ACG’s remarkable digital transformation, adopting breakthrough technologies that not only keep medicines safe, affordable, and accessible – but also vastly improve manufacturing and supply chains. Meanwhile, he has led a series of tuck-in acquisitions that ensure ACG pioneers continuously in terms of innovation and scale.
Passionate about converting ideas into growth opportunities, he supports entrepreneurial visions that solve real-world challenges. As an investor and mentor to more than 35 health-tech start-ups, guiding strategy, technology, expertise and networks, Karan seeks to consolidate the next generation of leadership – one that will secure better access and bridge availability across the global health industry.
Karan serves on the India Advisory Board for the India-Brazil Chamber of Commerce, is Co-Chair for FICCI LAC Regional Council, a key advisor to Nasscom, and an active contributor to the Global Lighthouse Network community of the World Economic Forum. Years of keen basketball-playing underpin his leadership, communication, and competitive spirit, and have brought about ACG-NBA Jump, a grassroots programme to give Indian basketballers a global platform.
Selwyn Noronha
CEO ACG CAPSULES
Selwyn Noronha
Richard Stedman
CEO ACG ENGINEERING
Richard Stedman
SR Shivshankar
CEO ACG PACKAGING MATERIALS
SR Shivshankar
Udit Singh
CEO ACG INSPECTION
Udit Singh
Sunil Jha
Chief Human Resource Officer
Sunil Jha
Werner Bongers
CEO SCITECH
Werner Bongers
Nitin Desai
Chief Commercial Officer
Nitin Desai
Parag Shah
Chief Financial Officer
Parag Shah
Shankar Gupta
Chief Sales Officer
Shankar Gupta
Balajikasiram Sundararajan
Chief Digital Officer
Balajikasiram Sundararajan
Alexander Robertson
Chief Marketing Officer
Alexander Robertson
Boilerplate
For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better.
As the world’s most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards.
Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents.
Together, we share a common purpose: to solve the world’s greatest health challenges and make it better for everybody we serve.
